secwatch.observer — SEC 8-K summary
======================================

Issuer:     Centessa Pharmaceuticals plc (CNTA)
CIK:        0001847903
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001847903-23-000192
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Centessa SerpinPC Phase 2a Part 5 results: 96% median ABR reduction
-------------------------------------------------------------------

- Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline of 35.6.
- No thromboembolic events or treatment-related sustained D-dimer elevations observed.
- Total target joints reduced by 94% (from 53 to 3) by end of Part 5.
- Registrational PRESent-2 and PRESent-3 studies for hemophilia B are ongoing.
- No SerpinPC-related adverse events reported in Part 5; favorable safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/0001847903-23-000192-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847903/000184790323000192/cnta-20231210.htm
  HTML page:      https://secwatch.observer/filing/0001847903-23-000192

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer